4536.T
4536.T
JP3336000009
SANTEN PHARMACEUTICAL CO
Loading chart...
Pure Price Volatility Risk (Market Swings)

The business itself is financially solid (Financial Health 80/100, minimal insolvency risk). The high overall score (7/7) is driven primarily by extreme stock price swings (±26.8% p.a.) and steep historical drawdowns.

Volatility Risk

Transparent evaluation of price volatility (SRI), Beta, and historical drawdowns.

Volatility Risk Score
7/7 Very High
7 / 7 SRI Price Fluctuation & Beta

Very high volatility or fundamental risks. Significant loss potential; strictly for aggressive investors.

Beta (Market Relation)
-
Defensive
Volatility (5Y p.a.)
26.8% p.a.
5-Year Horizon
Max Drawdown (5Y)
-42.6%
5-Year Horizon
Sharpe Ratio
-0.02
Return / Risk
Speculative / High Risk: Score Basis:

Multi-Horizon Risk & Performance Matrix

Historical volatility, drawdowns, and risk-adjusted return across 1, 3, 5, and 10 years.

Timeframe
Volatility (p.a.)
Max Drawdown
Sharpe Ratio
Return (p.a.)
1 Year — — — +7.8%
3 Years 28.1% -30.0% 0.16 +7%
5 Years 26.8% -42.6% -0.02 +2.2%
10 Years 27.5% -56.3% -0.05 +1%

Automated Risk & Health Notes (Red Flags)

Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Exemplary balance sheet strength: Very solid ratio of equity to debt.
Historical Stress Test: Maximum peak-to-trough drawdown of -56.3% in the extended horizon.

Corporate Governance & ISS Scores

Shareholder rights, board structure and audit safety (Scale 1 = Low Risk, 10 = High Risk)
Overall Governance Risk
2 ISS Score: 2 / 10
Audit Risk
1 ISS Score: 1 / 10
Board Risk
4 ISS Score: 4 / 10
Short Ratio
-
ende